<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930394</url>
  </required_header>
  <id_info>
    <org_study_id>Ponatinib Cardiotoxicity</org_study_id>
    <nct_id>NCT03930394</nct_id>
  </id_info>
  <brief_title>Vascular Cardiotoxicity of Ponatinib</brief_title>
  <official_title>Vascular Cardiotoxicity of Ponatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-clinical studies suggest that the third generation tyrosine kinase inhibitor ponatinib
      can result in microvascular angiopathy and acceleration of atherosclerosis. This study is
      intended to examine for myocardial microvascular angiopathy and changes in carotid plaque in
      patients receiving ponatinib as part of their clinical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will perform serial echocardiography for ventricular function, myocardial
      contrast echocardiography for microvascular perfusion assessment, blood analysis for
      myocardial injury, and carotid US for plaque or IMT progression in subjects receiving
      ponatinib. This series of tests is intended to provide information on the presence of
      clinically-evident or subclinical microvascular angiopathy and plaque acceleration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence versus absence of any myocardial perfusion defect assessed by visual analysis for any abnormalities of microvascular flux rate (beta function) or microvascular blood volume during an infusion of ultrasound microbubble contrast agents.</measure>
    <time_frame>6 months</time_frame>
    <description>Contrast ultrasound perfusion imaging will be performed using power-modulation imaging and infusion of an ultrasound contrast agent. Destruction replenishment kinetics will be assessed visually by examination of delayed replenishment of signal intensity (&gt;5 seconds) after a high-mechanical index burst sequence, or abnormalities in plateau intensity reflecting regional abnormalities in myocardial microvascular blood volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence versus absence of any myocardial perfusion defect assessed by visual analysis for any abnormalities of microvascular flux rate (beta function) or microvascular blood volume during an infusion of ultrasound microbubble contrast agents.</measure>
    <time_frame>12 months</time_frame>
    <description>Contrast ultrasound perfusion imaging will be performed using power-modulation imaging and infusion of an ultrasound contrast agent. Destruction replenishment kinetics will be assessed visually by examination of delayed replenishment of signal intensity (&gt;5 seconds) after a high-mechanical index burst sequence, or abnormalities in plateau intensity reflecting regional abnormalities in myocardial microvascular blood volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid plaque size</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in IMT or plaque size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid plaque size</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in IMT or plaque size</description>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cardiotoxicity</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast ultrasound perfusion imaging</intervention_name>
    <description>Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.</description>
    <other_name>Carotid ultrasound</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with CML or ALL who are to be treated with ponatinib.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CML or ALL

          -  Prescribed ponatinib

        Exclusion Criteria:

          -  pregnancy or lactation

          -  major medical illness involving the heart or vasculature (CAD, PAD, DCM).

          -  hemodynamically unstable

          -  allergy to ultrasound contrast agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Melinda Wu, MD</last_name>
    <phone>503 494-4772</phone>
    <email>wume@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon HSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Wu, MD</last_name>
      <phone>503-494-9000</phone>
      <email>wume@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Lindner, MD</last_name>
      <phone>503494900</phone>
      <email>lindnerj@ohsu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, LÃ³pez JA, Lindner JR. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019 Apr 4;133(14):1597-1606. doi: 10.1182/blood-2018-10-881557. Epub 2019 Jan 28.</citation>
    <PMID>30692122</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jonathan R. Lindner, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

